Peptide
Sermorelin
Sermorelin is used or studied for stimulates natural gh release and related growth hormone, recovery and performance goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
In depth
How it works
Sermorelin is a synthetic fragment of growth hormone-releasing hormone (GHRH 1-29) that binds the GHRH receptor on the pituitary gland, prompting a pulse of the body's own GH release rather than supplying GH directly. Because the pituitary's own feedback loop — via the inhibitory hormone somatostatin — stays intact, proponents point to this mechanism as inherently self-limiting compared with injecting growth hormone itself.
Regulatory history and what the research shows
Sermorelin (brand name Geref) was FDA approved in 1997 for diagnosing and treating growth hormone deficiency in children. The manufacturer discontinued commercial production in 2008; the FDA's own determination confirms this was for business reasons, not safety or effectiveness.
More recent academic interest has focused on GHRH/sermorelin in older adults, alongside a 2006 review summarizing its mechanism-based safety case for adult GH insufficiency.
Safety and who should avoid it
Sermorelin has more clinical and regulatory history behind it than most other GH secretagogues, given its former FDA approval. Commonly reported effects include flushing, headache, and injection-site reactions. It is not currently sold as an FDA-approved product, so any present-day sourcing is unregulated or compounded rather than pharmaceutical-grade.
Detail
Overview
Sermorelin is used or studied for stimulates natural gh release and related growth hormone, recovery and performance goals. Potential benefits and safety depend on indication, formulation, dose, and medical supervision.
Benefits, side effects, and protocols
Benefits list
- Stimulates natural GH release
Side effects
- Flushing
- headache
Vendor protocol
- None listed
Clinical protocol
- None listed
Evidence
- Low
- Used as safer GH alternative
Regulatory
- Not Fda Approved
Research
Mechanisms
Evidence notes
- Low
- Used as safer GH alternative
Administration
Research links
Contraindications
- None listed
Components
- None listed
Regulatory data
- Not Fda Approved
Aliases
- None listed
Used in these stacks
Related compounds
Guides that cover Sermorelin
Terminology on this page
Concepts from the glossary that come up around Sermorelin.
A substance that causes a gland to secrete a hormone the body already makes, rather than supplying the hormone directly.
Growth hormone-releasing hormone — the hypothalamic signal that tells the pituitary to release growth hormone.
Insulin-like growth factor 1 — the hormone, made largely by the liver in response to growth hormone, that mediates most of growth hormone’s effects.
Frequently asked questions
Is sermorelin FDA approved?
It was FDA approved in 1997 as Geref for pediatric growth hormone deficiency. The manufacturer stopped producing it commercially in 2008 for business reasons — the FDA confirmed this was not due to safety or effectiveness concerns — and it is not currently marketed as an approved drug.
What is sermorelin used for?
Historically, diagnosing and treating growth hormone deficiency in children. More recently it has been studied and used off-label for GH-axis support in adults, including aging-related research contexts.
Sermorelin vs CJC-1295 — what's the difference?
Both are GHRH analogs. Sermorelin is the shorter-acting original with FDA precedent; CJC-1295 is a longer-acting synthetic follow-on that was never FDA approved.
Educational reference only. Pepperz does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing recommendations. Sourcing Sermorelin? Check your source before you use anything.